{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:22:49Z","timestamp":1787732569927,"version":"build-2784847793"},"reference-count":28,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int Forum Allergy Rhinol"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biologic treatments were introduced for chronic rhinosinusitis with nasal polyps (CRSwNP) in 2019. Treatment algorithms for medically refractory CRSwNP remain open, with patients choosing among surgery, biologics, or both. Real\u2010world utilization of surgery and biologics remains incompletely characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of the study is to evaluate temporal trends in endoscopic sinus surgery (ESS) and biologic utilization in relation to 2019 Food and Drug Administration approval of biologics for CRSwNP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective study of CRSwNP ESS and biologic prescription rates, patient demographics, and comorbidities within the Merative MarketScan Research database (2016\u20132024). Quarterly and annual trends were evaluated by regression and interrupted time series analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 59,953 CRSwNP patients were included. Annual ESS rates declined, whereas biologic prescriptions increased markedly from 2016 to 2024. Dupilumab dominated among biologic alternatives. Interrupted time series analysis demonstrated a sharp decline in ESS rates with the 2019 introduction of biologics for CRSwNP, whereas biologic use grew continuously across 2016\u20132024 with a large increase in 2019\u20132020. Combination ESS and biologic treatment is growing but remains relatively infrequent. Patients receiving biologics were older and suffered from type 2 inflammatory comorbidities, such as asthma and allergic rhinitis (\n                      <jats:italic>p<\/jats:italic>\n                      &lt;0.001 for both).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In CRSwNP, biologic treatment has increased significantly in recent years, particularly in older patients or those with type 2 inflammatory comorbidities. Overall ESS utilization in CRSwNP has declined, and combination ESS and biologics are an emerging phenomenon. These figures reveal the extent of evolution in CRSwNP treatment induced by targeted medical therapies in real\u2010world practice and serve as a foundation for healthcare utilization discussions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/alr.70256","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:11:16Z","timestamp":1787731876000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologics Adoption in CRSwNP and the Associated Decline in Endoscopic Sinus Surgery: A Longitudinal Claims Database Study"],"prefix":"10.1002","author":[{"given":"Stephanie Shintani","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2010Head and Neck Surgery Northwestern University Feinberg School of Medicine  Chicago, IL USA"},{"name":"Center for Health Services and Outcomes Research Institute for Public Health and Medicine Northwestern University Feinberg School of Medicine  Chicago, IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam L.","family":"Kaefer","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery Indiana University School of Medicine  Indianapolis, IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7952-463X","authenticated-orcid":false,"given":"Harsh","family":"Duvvuru","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery Indiana University School of Medicine  Indianapolis, IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Kern","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2010Head and Neck Surgery Northwestern University Feinberg School of Medicine  Chicago, IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1503-3150","authenticated-orcid":false,"given":"Brent A.","family":"Senior","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head &amp; Neck Surgery University of North Carolina \u2013 Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2748-0705","authenticated-orcid":false,"given":"Vijay R.","family":"Ramakrishnan","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology \u2013 Head and Neck Surgery Indiana University School of Medicine  Indianapolis, IN USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"29","key":"e_1_2_10_2_1","first-page":"1","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens W. J.","year":"2020","journal-title":"Rhinology"},{"issue":"3","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/alr.22741","article-title":"International Consensus Statement on Allergy and Rhinology: Rhinosinusitis 2021","volume":"11","author":"Orlandi R. R.","year":"2021","journal-title":"International Forum of Allergy & Rhinology"},{"key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/alr.21064","article-title":"Antimicrobials and Chronic Rhinosinusitis With or Without Polyposis in Adults: An Evidenced\u2010based Review With Recommendations","volume":"3","author":"Soler Z. M.","year":"2013","journal-title":"International Forum of Allergy & Rhinology"},{"issue":"3","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long\u2010Term Efficacy and Safety of Omalizumab for Nasal Polyposis in an Open\u2010Label Extension Study","volume":"149","author":"Gevaert P.","year":"2022","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and Safety of Omalizumab in Nasal Polyposis: 2 Randomized Phase 3 Trials","volume":"146","author":"Gevaert P.","year":"2020","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"8","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and Safety of Treatment With Biologicals for Severe Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review for the EAACI Guidelines","volume":"76","author":"Agache I.","year":"2021","journal-title":"Allergy"},{"issue":"12","key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in Adults With Severe Chronic Rhinosinusitis With Nasal Polyps","volume":"392","author":"Lipworth B. J.","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for Chronic Rhinosinusitis With Nasal Polyps (SYNAPSE): A Randomised, Double\u2010Blind, Placebo\u2010Controlled, Phase 3 Trial","volume":"9","author":"Han J. K.","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"issue":"10209","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and Safety of Dupilumab in Patients With Severe Chronic Rhinosinusitis With Nasal Polyps (LIBERTY NP SINUS\u201024 and LIBERTY NP SINUS\u201052): Results From Two Multicentre, Randomised, Double\u2010Blind, Placebo\u2010Controlled, Parallel\u2010Group Phase 3 Trials","volume":"394","author":"Bachert C.","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"e_1_2_10_11_1","first-page":"194","article-title":"EPOS\/EUFOREA Update on Indication and Evaluation of Biologics in Chronic Rhinosinusitis With Nasal Polyps 2023","volume":"61","author":"Fokkens W. J.","year":"2023","journal-title":"Rhinology"},{"issue":"2","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jaci.2022.10.026","article-title":"The Joint Task Force on Practice Parameters GRADE Guidelines for the Medical Management of Chronic Rhinosinusitis With Nasal Polyposis","volume":"151","author":"Rank M. A.","year":"2023","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"9","key":"e_1_2_10_13_1","first-page":"2642","article-title":"The Management of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) With Biologics","volume":"11","author":"Wautlet A.","year":"2023","journal-title":"Journal of Allergy and Clinical Immunology: In Practice"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA Consensus on Biologics for CRSwNP With or Without Asthma","volume":"74","author":"Fokkens W. J.","year":"2019","journal-title":"Allergy"},{"issue":"2","key":"e_1_2_10_15_1","first-page":"S1","article-title":"Clinical Practice Guideline: Surgical Management of Chronic Rhinosinusitis","volume":"172","author":"Shin J. J.","year":"2025","journal-title":"Otolaryngology \u2013 Head and Neck Surgery"},{"issue":"8","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4193\/RHINOL\/24.003","article-title":"Trends in Dupilumab Persistence Among Patients With Chronic Rhinosinusitis With Nasal Polyps","volume":"7","author":"Stack T. J.","year":"2024","journal-title":"Rhinology Online"},{"key":"e_1_2_10_17_1","volume-title":"CDC Museum COVID\u201019 Timeline","author":"Centers for Disease Control and Prevention"},{"key":"e_1_2_10_18_1","volume-title":"FDA Approves First Treatment for Chronic Rhinosinusitis With Nasal Polyps","author":"U.S. Food and Drug Administration","year":"2019"},{"issue":"1","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/alr.20101","article-title":"Nationwide Incidence of Major Complications in Endoscopic Sinus Surgery","volume":"2","author":"Ramakrishnan V. R.","year":"2012","journal-title":"International Forum of Allergy & Rhinology"},{"issue":"1","key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/19458924241287959","article-title":"Practice Patterns of Biologics Prescriptions and Surgery in Chronic Rhinosinusitis With Nasal Polyps","volume":"39","author":"Almarri F. K.","year":"2025","journal-title":"American Journal of Rhinology & Allergy"},{"issue":"2","key":"e_1_2_10_21_1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/lary.31774","article-title":"Impact of Biologics on Surgery in Chronic Rhinosinusitis With Polyps and Allergic Fungal Sinusitis","volume":"135","author":"Bentan M. A.","year":"2025","journal-title":"Laryngoscope"},{"issue":"1","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13223-023-00855-7","article-title":"Biologic Use and Treatment Patterns in Patients With Chronic Rhinosinusitis With Nasal Polyps: A US Real\u2010World Study","volume":"19","author":"Silver J.","year":"2023","journal-title":"Allergy, Asthma, and Clinical Immunology: Official Journal of the Canadian Society of Allergy and Clinical Immunology"},{"issue":"4","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jamaoto.2020.5286","article-title":"Evalaution of Diffuse Type 2 Dominant or Eosinophilic Chronic Rhinosinusitis With Corticosteroid Irrigation After Surgical Neosinus Cavity Formation","volume":"147","author":"Li W.","year":"2021","journal-title":"JAMA Otolaryngology Head Neck Surgery"},{"issue":"1","key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/alr.23043","article-title":"Efficacy of the Exhalations Delivery System With fluticasone in Patients With Crhonic Rhinosinusitis With Nasal Polyps Whose Symptoms Recur After Surgery","volume":"13","author":"Ow R.","year":"2023","journal-title":"International Forum of Allergy & Rhinology"},{"issue":"3","key":"e_1_2_10_25_1","first-page":"1107","article-title":"Cost\u2010Effectiveness of Biologics for Allergic Diseases","volume":"9","author":"Wu A. C.","year":"2021","journal-title":"Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"1","key":"e_1_2_10_26_1","doi-asserted-by":"crossref","first-page":"E26","DOI":"10.1002\/lary.28648","article-title":"Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps","volume":"131","author":"Scangas G. A.","year":"2021","journal-title":"Laryngoscope"},{"issue":"3","key":"e_1_2_10_27_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.21053\/ceo.2024.00310","article-title":"The Efficacy of Dupilumab as an Adjuvant Treatment After Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps: A Retrospective Cohort Analysis","volume":"18","author":"Liu C. N.","year":"2025","journal-title":"Clinical and Experimental Otorhinolaryngology"},{"issue":"6","key":"e_1_2_10_28_1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.anorl.2024.11.011","article-title":"Impact of Residual Ethmoidal Laminae on Dupilumab Efficacy Following Endoscopy Sinus Surgery in Patients With Chronic Rhinosinusitis: A STROBE Analysis","volume":"142","author":"Yanagi N.","year":"2025","journal-title":"European Annals of Otorhinolaryngol Head Neck Diseases"},{"key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/alr.23471","article-title":"Perioperative Adjuvant Therapy With Short Course of Dupilumab With ESS for Recurrent CRSwNP","volume":"15","author":"Pelletier A.","year":"2025","journal-title":"International Forum of Allergy & Rhinology"}],"container-title":["International Forum of Allergy &amp; Rhinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alr.70256","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/alr.70256","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alr.70256","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T08:11:21Z","timestamp":1787731881000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/alr.70256"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":28,"alternative-id":["10.1002\/alr.70256"],"URL":"https:\/\/doi.org\/10.1002\/alr.70256","archive":["Portico"],"relation":{},"ISSN":["2042-6976","2042-6984"],"issn-type":[{"value":"2042-6976","type":"print"},{"value":"2042-6984","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"2026-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"alr.70256"}}